Rennert 先生自 2008 年起擔任公司規模最大的業務部門總裁，並於 2016 年被任命為 ZOLL 的執行長。在 Rennert 先生的領導下，ZOLL 擴大了其作為體外心臟電擊去顫領域全球領導者的影響力，為患有嚴重心肺和呼吸系統疾病的廣大病患開創了新穎的解決方案，並透過多次收購擴大其產品組合。
在加入 ZOLL 之前，Rennert 先生曾引領 PerkinElmer, Inc. 的分析儀器業務，並在聯合技術公司（現更名為開利全球公司）和奇異公司擔任製造和工程領域的領導職務。
Rennert 先生擁有麻省理工學院史隆管理學院的管理研究碩士學位、麻省理工學院的機械工程碩士學位，以及普林斯頓大學的機械暨航太工程學士學位。
Mr. White was named President of the ZOLL Acute Care Technology division in April 2024, after serving as President of ZOLL Resuscitation for more than five years. He joined ZOLL as Vice President of Marketing in 2012 with responsibilities for the global marketing and strategy of the company's resuscitation portfolio. Prior to ZOLL, Mr. White led North American marketing efforts at Haemonetics. Earlier, he held general management and marketing leadership positions at Orthofix and Medtronic cardiology. Mr. White has also served as a submarine officer in the U.S. Navy and holds an MBA and a B.A. from Harvard University.
Mr. Blastick joined ZOLL as President of the Cardiac Management Solutions division in April 2024. Prior to joining ZOLL, Mr. Blastick was President of Aesculap, a B. Braun Company. From 2006 to 2021, he worked in a variety of executive roles at Boston Scientific. Mr. Blastick holds an MBA from the Kellogg School of Management at Northwestern University and a bachelor's degree in Accounting from Indiana University.
Prior to being named President of ZOLL Respicardia in 2022, Mr. Anderson spent four years as Vice President of Marketing and Market Access for Respicardia. In that role, he served as the commercial lead for marketing, reimbursement, medical education, physician training, and sales operations, and led the go-to-market strategy for Respicardia's remedē® System. Prior to joining Respicardia, Mr. Anderson spent 15 years at Boston Scientific in a variety of leadership roles focused on global marketing, strategic and tactical planning, channel strategies, and product management. He holds an MBA from the Tuck School of Business at Dartmouth College, and a bachelor's degree in engineering from North Dakota State University.
Mr. Knudsen became President of ZOLL Itamar in 2022, after leading ZOLL's Corporate Development efforts - including the company's strategic investments and M&A activities - for six years. Prior to joining ZOLL in 2013, Mr. Knudsen held leadership positions in Corporate and Business Development, Marketing, and Sales at Covidien (now Medtronic), Aspect Medical Systems, and LeMaitre Vascular. He earned his National EMS Certification and is a licensed EMT in Massachusetts. Mr. Knudsen holds an MBA from the Thunderbird School of Global Management and bachelor's degrees in both Political Science and Communications from Boston College.
Ms. Hersey leads ZOLL's global Human Resources organization, which includes Employee Compensation and Benefits, HR Information Systems, Learning and Development, Employee Communications, and Corporate Events. Before joining ZOLL in 2018, Ms. Hersey served in senior leadership roles in Human Resources at TD Bank; Fidelity Investments; and Cigna, a global healthcare company. She holds a juris doctor degree from the Western New England University School of Law and a bachelor's degree in English from the University of Connecticut.
Mr. Grossman, who joined ZOLL in 2011, leads the company's Legal Department, which includes corporate and divisional legal teams, as well as Compliance, Privacy and Governance, and Intellectual Property. In this role, he is responsible for managing all aspects of the company's legal function, including mergers and acquisitions, commercial contracts, employment, corporate governance, intellectual property, and litigation. Prior to ZOLL, he served in a similar capacity at LeMaitre Vascular, Inc., a publicly traded medical device company based in Burlington, Mass., with operations in 15 countries. Earlier, from 1999 to 2002, Mr. Grossman was a Corporate Attorney at Goulston & Storrs in Boston. He received a bachelor's degree in political science from Vassar College, a master's degree in law and diplomacy from the Fletcher School of Law and Diplomacy at Tufts University, and a juris doctor degree from Harvard Law School.
Mr. Stowell was named Chief Financial Officer in 2022 after serving as Vice President, Corporate Controller since 2013. He joined the company in 2003, serving in various finance roles, including planning and budgeting, business development, and corporate governance. Prior to ZOLL, Mr. Stowell was employed by Narad Networks, an early-stage technology company. Earlier, he was an Audit Manager at Deloitte & Touche LLP in Boston. He received a bachelor's degree in accounting from the University of Massachusetts and subsequently earned his CPA license.
Ms. Landis is responsible for identifying, assessing, and negotiating opportunities to expand ZOLL's global portfolio of businesses. In this role, she leads ZOLL's early-stage venture investment and M&A activities, as well as ZOLL's short- and long-term growth planning. Prior to joining ZOLL in 2016, Ms. Landis served in leadership positions in corporate development, management consulting, venture capital and public equity direct investing, all with a focus on the medical device industry. She holds an MBA from Babson's Olin School of Business and a bachelor's degree in Political Science from Emory University.